SCHEDULE: Millennium Entities Disclose ANI Pharma Stake

Millennium Management and affiliated entities have disclosed beneficial ownership of up to 0.3% of ANI Pharmaceuticals, Inc. common stock as of September 30, 2025.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 1 to Schedule 13G.
• The filing discloses beneficial ownership of common stock in ANI Pharmaceuticals, Inc. (CUSIP: 00182C103).
• As of September 30, 2025, Integrated Core Strategies (US) LLC beneficially owned 53,769 shares, representing 0.2% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially owned 65,245 shares, representing 0.3% of the class.
• All reporting persons hold shared voting power and shared dispositive power over their respective reported shares.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by institutional investors. The percentages are small, indicating a passive investment rather than an activist stance, thus having a neutral impact.

Positives

• Disclosure of institutional ownership by Millennium Management and its affiliates, indicating their investment interest in ANI Pharmaceuticals, Inc.
• Transparency in reporting beneficial ownership as required by SEC regulations.

Negatives

• The disclosed ownership percentages (0.2% and 0.3%) are relatively small, suggesting a limited impact on the company's control or strategic direction.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the issuer's future outlook.

Industry Context

This filing is a routine disclosure of beneficial ownership by institutional investors and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, confirming that Millennium Management and its affiliates hold a stake in ANI Pharmaceuticals, Inc.
• Management: Awareness of institutional investor interest, though the stake is not large enough to imply immediate pressure or influence.

Key Dates

Recommendation

This filing is a routine disclosure of a relatively small, passive stake by institutional investors. It does not provide new fundamental information about ANI Pharmaceuticals, Inc.'s operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should continue to evaluate the company based on its core business fundamentals and other financial disclosures.

Keywords

ANI Pharmaceuticals, Common Stock, Schedule 13G, Beneficial Ownership, Millennium Management, Integrated Core Strategies, Israel A. Englander, Institutional Investor, SEC Filing